A Multicenter Phase 1, Open-Label Study of DCC-2618 to Assess Safety, Tolerability, and Pharmacokinetics in Patients With Advanced Malignancies

Trial Profile

A Multicenter Phase 1, Open-Label Study of DCC-2618 to Assess Safety, Tolerability, and Pharmacokinetics in Patients With Advanced Malignancies

Recruiting
Phase of Trial: Phase I

Latest Information Update: 20 Nov 2017

At a glance

  • Drugs DCC 2618 (Primary)
  • Indications Gastrointestinal stromal tumours; Glioblastoma; Glioma; Haematological malignancies; Solid tumours; Systemic mastocytosis
  • Focus Adverse reactions; First in man; Proof of concept
  • Sponsors Deciphera Pharmaceuticals
  • Most Recent Events

    • 20 Nov 2017 According to a Deciphera Pharmaceuticals media release, results from patients with malignant glioma in this trial were presented at the 22nd Annual Scientific Meeting and Education Day of the Society for Neuro-Oncology.
    • 14 Nov 2017 According to a Deciphera Pharmaceuticals media release, updated data was presented at the European Society for Medical Clinical Oncology 2017 Congress (ESMO).
    • 10 Nov 2017 Results published in the Deciphera Pharmaceuticals Media Release
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top